GLP-1 maintenance phase: what the science says about stopping

What did @nicloseslbs actually say?

The creator is four weeks into GLP-1 maintenance and still losing weight, which is not their goal. They say they've been staying on "the same dose of 7.5 milligrams" and spacing injections out every nine days, and they're now considering spacing doses out further to slow continued loss. They also express concern about becoming "that stereotype" of someone who loses too much on GLP-1 therapy.

This is a candid, personal update, not a medical how-to. The creator is documenting lived experience, not prescribing a protocol. That framing matters when evaluating what they got right and wrong.

Does the science back this up?

Mostly, yes. The concept that maintenance on GLP-1 medications requires active dose adjustment is well-supported. The evidence for how to actually do that, though, is thinner than most creators let on.

The landmark STEP 1 extension trial (Wilding et al., 2022, New England Journal of Medicine) showed that participants who stopped semaglutide regained about two-thirds of their lost weight within a year. That data strongly suggests GLP-1 maintenance is an active process, not a passive one. What the clinical literature does not have is a robust, peer-reviewed protocol for using extended dosing intervals to stabilize weight rather than continue losing. That gap matters. The creator is essentially improvising a strategy that hasn't been validated in controlled trials.

Tirzepatide, which 7.5 mg likely refers to (this is a standard Mounjaro/Zepbound dose), has shown dose-dependent weight loss in the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine). Lowering effective drug exposure to slow weight loss is pharmacologically reasonable, but the precise mechanics of interval stretching haven't been studied with the rigor that would let anyone say confidently it works as intended.

What did they get wrong (or right)?

They got the core intuition right. If you're losing more weight than you want on a GLP-1, reducing drug exposure makes pharmacological sense. The body's response to GLP-1 agonists is dose-dependent, so less drug generally means less appetite suppression and less weight loss over time. Credit where it's due.

What's shakier is the implied framing that spacing out doses is a reliable, predictable maintenance tool. There's no strong clinical evidence that interval stretching produces a consistent, controllable plateau. Individual responses vary considerably, and some people may find that extended intervals lead to rebound hunger cycles rather than smooth stabilization. A 2023 review in Obesity Reviews (Arillotta et al.) noted that off-label dosing modifications are common in practice but largely unstudied.

The "stereotype" comment is culturally interesting but medically vague. It's not a clinical claim, so there's nothing to fact-check there beyond noting that body image concerns are legitimate motivators that clinicians often underweight in maintenance conversations.

What should you actually know?

GLP-1 maintenance is genuinely under-researched relative to how many people are now attempting it. Most major trials studied weight loss endpoints, not stabilization strategies. That leaves a real clinical gap that creators like this one are filling with personal experimentation, which has value as lived experience but is not a substitute for medical guidance.

A few things the evidence does support: weight regain after stopping GLP-1 therapy is common and rapid (Wilding et al., 2022). Continued therapy at some dose level appears necessary for most people to maintain results. And individual variability in response is high, which is why the creator's framing of maintenance as "trial and error" is, honestly, accurate.

If you're in a similar situation, interval stretching is something to discuss with a prescribing clinician, not something to self-manage based on TikTok timelines. The 7.5 mg dose mentioned is a specific prescription dose, and any modifications to injection schedules should be supervised.

Is there anything missing from this conversation?

Yes. Caloric intake and protein targets are conspicuously absent. GLP-1 medications suppress appetite, but weight stabilization also depends on what you're actually eating. The SURMOUNT-1 and STEP trials both included dietary counseling alongside medication. Dose manipulation alone is an incomplete maintenance strategy.

There's also no mention of muscle mass, which is a real concern during GLP-1-associated weight loss. A 2023 analysis in Diabetes Care (Bikou et al.) found that lean mass loss accompanies fat loss on semaglutide, and that resistance training can partially offset this. Someone losing more weight than desired should probably be asking about body composition, not just the number on the scale.